A Preliminary in Silico Lead Series of 2-Phthalimidinoglutaric Acid Analogues Designed as MMP-3 Inhibitors
- 12 July 2006
- journal article
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 46 (5), 2104-2109
- https://doi.org/10.1021/ci0601362
Abstract
Matrix metalloproteinases (MMPs) have been the subject of intense research because of their roles in tumor metastasis and in the rise and spread of degenerative diseases such as osteo- and rheumatoid arthritis. A preliminary class of 140 druglike, small-molecule matrix metalloproteinase-3 inhibitors, intended as starting scaffolds for optimization and synthesis, has been designed in silico using a series of highly predictive three-dimensional quantitative structure−activity relationship models, including comparative molecular field analysis and comparative molecular similarity indices analysis, with docking and scoring. Thalidomide was chosen as the skeleton on which to base the new lead series, as it moderately inhibits MMP-3, is antiangiogenic, and lends itself easily to structural modifications. Most of the new compounds demonstrate medium to high predicted biological activity and good bioavailability as estimated by the octanol−water partition coefficient ClogP. Compound 102 in particular exhibits extremely favorable predicted activity against MMP-3; is moderately bioavailable; satisfies Lipinski's Rule of Five; and shows promise for further optimization, synthesis, and experimental evaluation as a potential adjunct anticancer or antirheumatic therapeutic.This publication has 28 references indexed in Scilit:
- Effects of alendronate and hormone replacement therapy, alone and in combination, on saliva, periodontal conditions and gingival crevicular fluid matrix metalloproteinase-8 levels in women with osteoporosisOral Diseases, 2006
- Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancerBreast Cancer Research and Treatment, 2005
- Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritisArthritis & Rheumatism, 2005
- IMiDs: A Novel Class of ImmunomodulatorsSeminars in Oncology, 2005
- Expression of MMP2, MMP9 and MMP3 in Breast Cancer Brain Metastasis in a Rat ModelClinical & Experimental Metastasis, 2005
- Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell linesExperimental Cell Research, 2005
- Increased plasma MMP9 in integrin α1‐null mice enhances lung metastasis of colon carcinoma cellsInternational Journal of Cancer, 2005
- Molecular Properties That Influence the Oral Bioavailability of Drug CandidatesJournal of Medicinal Chemistry, 2002
- Structure of Human Pro-Matrix Metalloproteinase-2: Activation Mechanism RevealedScience, 1999
- Molecular Similarity Indices in a Comparative Analysis (CoMSIA) of Drug Molecules to Correlate and Predict Their Biological ActivityJournal of Medicinal Chemistry, 1994